A Mendelian analysis supports a causal effect of hyperglycemia on stroke risk, and the researchers also pinpoint the medications most likely to reduce this risk.
People with obesity continue to lose weight if they remain on semaglutide 2.4 mg after an initial 20 weeks of treatment, but gradually regain it if they switch to placebo, show the STEP 4 findings.
Domenica Rubino discusses the chronicity of obesity, and how STEP 4 demonstrates the need for long-term semaglutide treatment to avoid weight regain (5:59).